新一代流式细胞术用于多发性骨髓瘤微小残留病的高灵敏度标准化检测
该研究构建了优化双管8色抗体组合与自动浆细胞设门软件,采用大体积裂解获取每样本≥10^7个细胞,在多中心110份多发性骨髓瘤患者随访骨髓标本中评估新一代流式细胞术(NGF)检测微小残留病(MRD)的性能。NGF-MRD阳性率为47%,常规8色流式为34%(P=0.003);常规流式判为MRD阴性的患者中25%经NGF判为阳性,NGF判为MRD阴性的完全缓解患者无进展生存期显著长于阳性者(75%无进展生存未达到 vs 7个月;P=0.02)。
要点
- NGF-MRD阳性率47% vs 常规8色流式34%(P=0.003)。
- 常规流式判为MRD阴性的患者中25%经NGF判为阳性。
- NGF判为MRD阴性的完全缓解患者无进展生存期显著优于阳性者。
核心结论
- 基于EuroFlow的新一代流式细胞术(NGF)是多发性骨髓瘤MRD检测的高灵敏度、完全标准化方法,克服了常规流式MRD的主要局限,已可用于常规诊断。
研究设计与样本
- 研究构建了经五轮设计-评估-再设计优化的双管8色抗体组合,建立大体积裂解流程以获取每样本≥10^7个细胞,并开发自动浆细胞设门软件。
- 多中心评估110份处于非常好的部分缓解(VGPR)或完全缓解(CR)的多发性骨髓瘤患者随访骨髓标本。
主要发现
- NGF-MRD阳性率为47%,常规8色流式MRD阳性率为34%(P=0.003)。
- 常规8色流式判为MRD阴性的患者中,25%经NGF判为MRD阳性。
- NGF判为MRD阴性的完全缓解患者无进展生存期显著长于NGF判为MRD阳性的完全缓解患者(75%无进展生存未达到 vs 7个月;P=0.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple myeloma (MM) after therapy. However, current flow-MRD has lower sensitivity than molecular methods and lacks standardization. Here we report on a novel next generation flow (NGF) approach for highly sensitive and standardized MRD detection in MM. An optimized 2-tube 8-color antibody panel was constructed in five cycles of design-evaluation-redesign. In addition, a bulk-lysis procedure was established for acquisition of ⩾107 cells/sample, and novel software tools were constructed for automatic plasma cell gating. Multicenter evaluation of 110 follow-up BM from MM patients in very good partial response (VGPR) or CR showed a higher sensitivity for NGF-MRD vs conventional 8-color flow-MRD -MRD-positive rate of 47 vs 34% (P=0.003)-. Thus, 25% of patients classified as MRD-negative by conventional 8-color flow were MRD-positive by NGF, translating into a significantly longer progression-free survival for MRD-negative vs MRD-positive CR patients by NGF (75% progression-free survival not reached vs 7 months; P=0.02). This study establishes EuroFlow-based NGF as a highly sensitive, fully standardized approach for MRD detection in MM which overcomes the major limitations of conventional flow-MRD methods and is ready for implementation in routine diagnostics.
引用
- Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017. PMID: 28104919. doi:10.1038/leu.2017.29
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。